Allergen-specific immunotherapy induces regulatory T cells in an atopic dermatitis mouse model

Allergy ◽  
2018 ◽  
Vol 73 (9) ◽  
pp. 1801-1811 ◽  
Author(s):  
J. U. Shin ◽  
S. H. Kim ◽  
J. Y. Noh ◽  
J. H. Kim ◽  
H. R. Kim ◽  
...  
PLoS ONE ◽  
2015 ◽  
Vol 10 (8) ◽  
pp. e0135070 ◽  
Author(s):  
Nadezda Shershakova ◽  
Elena Bashkatova ◽  
Alexander Babakhin ◽  
Sergey Andreev ◽  
Alexandra Nikonova ◽  
...  

2011 ◽  
Vol 22 (1) ◽  
pp. 15-23 ◽  
Author(s):  
Cengiz Kirmaz ◽  
Ozlem Ozenturk Kirgiz ◽  
Papatya Bayrak ◽  
Ozge Yilmaz ◽  
Seda Vatansever ◽  
...  

2014 ◽  
Vol 194 (3) ◽  
pp. 887-897 ◽  
Author(s):  
Livia Böhm ◽  
Joachim Maxeiner ◽  
Helen Meyer-Martin ◽  
Sebastian Reuter ◽  
Susetta Finotto ◽  
...  

2020 ◽  
Vol 48 (12) ◽  
pp. 030006052098094
Author(s):  
Shuang Qin ◽  
Li Li ◽  
Jia Liu ◽  
Jinrui Zhang ◽  
Qing Xiao ◽  
...  

Objective The present study aimed to evaluate the effects of cluster of differentiation (CD)4+CD25+ forkhead box p3 (Foxp3)+ regulatory T cells (Tregs) on unexplained recurrent spontaneous abortion (URSA) and the associated mechanisms. Methods The proportion of CD4+CD25+Foxp3+ Tregs and inflammatory cytokine concentrations in the peripheral blood of women with URSA were measured by flow cytometry and enzyme-linked immunosorbent assay, respectively. CBA/JxDBA/2J mating was used to establish an abortion-prone mouse model and the model mice were treated with the Toll-like receptor 4 (TLR4) antagonist E5564 and the TLR4 agonist lipopolysaccharide. Results The proportion of CD4+CD25+Foxp3+ Tregs was decreased and the inflammatory response was increased in women with URSA. In the abortion-prone mouse model, E5564 significantly increased the proportion of CD4+CD25+Foxp3+ Tregs, decreased the inflammatory response, and increased Foxp3 mRNA and protein expression. Lipopolysaccharide had adverse effects on the abortion-prone model. Conclusions These data suggest that CD4+CD25+Foxp3+ Tregs regulate immune homeostasis in URSA via the TLR4/nuclear factor-κB pathway, and that the TLR4 antagonist E5564 may be a novel and potential drug for treating URSA.


Sign in / Sign up

Export Citation Format

Share Document